Replimune Group (NASDAQ:REPL) Director Sells $408,500.00 in Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Kapil Dhingra sold 21,500 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.00, for a total value of $408,500.00. Following the completion of the sale, the director owned 21,669 shares of the company’s stock, valued at $411,711. This trade represents a 49.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Up 6.0%

NASDAQ REPL traded up $1.16 on Tuesday, reaching $20.65. 4,728,562 shares of the stock traded hands, compared to its average volume of 2,758,501. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $21.26. The firm’s fifty day simple moving average is $13.79 and its 200 day simple moving average is $9.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. On average, analysts predict that Replimune Group, Inc. will post -2.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Replimune Group during the 3rd quarter worth $64,000. Vise Technologies Inc. acquired a new position in shares of Replimune Group in the 3rd quarter worth $163,000. China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 30.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after purchasing an additional 4,050 shares during the period. Maxi Investments CY Ltd acquired a new stake in shares of Replimune Group during the third quarter worth $556,000. Finally, Opaleye Management Inc. acquired a new stake in shares of Replimune Group during the second quarter worth $15,332,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on REPL shares. Leerink Partners lifted their target price on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a report on Monday, October 5th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.